Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

AML
AML With Mutated NPM1
Hematologic Malignancy
KMT2Ar
NPM1 Mutation
MLL Rearrangement
Leukemia
Acute Myeloid Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Acute Leukemia
Neoplasms by Histologic Type

Interventions

DRUG: Ziftomenib
DRUG: Fludarabine
DRUG: Idarubicin
DRUG: Cytarabine
DRUG: Gilteritinib
BIOLOGICAL: Granulocyte colony-stimulating factor

Sponsor

Kura Oncology, Inc.